Patient Capital Quarterly Commentary – Q3 2025

The third quarter of 2025 closed with a broad-based – rally across North American equities, underpinned by an inflection toward lower interest rates and a resilient U.S. economy. In the United States, the S&P 500 Index delivered strong quarter and year-to-date returns in an increase that moved beyond large caps as rate expectations eased, and earnings met or surpassed consensus estimates. This equity strength arrived alongside the Federal Reserve’s September 17, 2025, decision to cut the policy rate by 25 bps—to a 4.00%– 4.25% target range—and a signal that the Federal Reserve would proceed meeting-by-meeting given softer hiring and a cooler labour backdrop. 

Canada’s equity market decisively outpaced the U.S. in the third quarter. The S&P/TSX Composite Index was boosted by a powerful rally in precious metals. The financial sector also rallied as domestic interest rates fell. The Bank of Canada reduced interest rates by 25 basis points to 2.50% on September 17, 2025, explicitly citing slower activity and contained inflation. Canadian economic data pointed to a weakening economy with real GDP contracting in the second quarter and unemployment levels remaining elevated.

In our view, broad based equity valuations are now in speculative territory in both the U.S. and Canada. The American market has been driven by the excitement and promise of Artificial Intelligence (AI). Investors believe that AI will create both an investment and productivity boom. Along with the prospect of declining interest rates, investors’ optimism has reached levels seen in other speculative bubbles. In our opinion, a very serious concern is the substantial flows into crypto currencies. In many cases, leveraged investment vehicles have been created to invest in crypto assets. 

In Canada, the rise in equities has been largely due to precious metals, and in particular, gold. Gold is traditionally seen as a hedge against inflation and economic instability. At over $4,000 USD per ounce, the price of gold is now at all time highs. Investors are increasingly concerned about ballooning government debt, potential inflation, and the worry around political interference in central bank policy. In our view, gold continues to attract investors seeking stability in the face of global political unrest and economic unpredictability.

The chart below indicates the elevated valuation of U.S. equities relative to historical norms.i

We believe Lysander-Patient Capital Equity Fund (the “Fund”) continues to be well positioned for current market conditions, and that a significant cash balance positions the Fund favourably, should markets become volatile. We have recently initiated new positions in companies with long operating records and sound balance sheets. In addition, we are of the view that the portfolio’s overall characteristics compare favorably to major benchmarks such as the S&P 500 Index and the S&P/TSX Composite Index.

iWanderer Financial

Lysander Funds Limited (“Lysander”) is the investment fund manager of Lysander-Patient Capital Equity Fund (the “Fund”). Patient Capital Management (“Patient Capital”) is the portfolio manager of the Fund. This document was prepared by Patient Capital as portfolio manager of the Fund. In this presentation, “we”, “us”, and “our” means Patient Capital. This document has been prepared solely for information purposes. Information in this document is not intended to constitute legal, tax, securities or investment advice and is made available on an “as is" basis. Neither Lysander nor Patient Capital make any warranties or representations regarding the information herein. Information in this document is subject to change without notice. Neither Lysander nor Patient Capital assume any duty to update any information herein. Certain information in this document has been derived or obtained from sources believed to be trustworthy and/or reliable. Neither Lysander nor Patient Capital assume responsibility for the accuracy, currency, reliability or correctness of any such information.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated

This document is not an invitation to invest in the Fund and does not constitute a public offering of sale. Purchases in the Fund can only be made through an Investment Professional on the terms in the applicable Fund’s offering document by eligible investors. Each purchaser of units in a fund may have statutory or contractual right of action.

This document may contain forward-looking statements. Statements concerning a Fund’s or entity’s objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition are forward looking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “aims”, “may”, “will”, “would” and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations. Readers are cautioned not to place undue reliance on these forward-looking statements. While Lysander and Patient Capital consider these risks and uncertainties to be reasonable based on information currently available, they may prove to be incorrect.

Nothing in this document should be considered a recommendation to buy, sell or short a particular security. Any specific securities or positions discussed are intended as an illustration of the portfolio manager’s selection process. The portfolio manager may sell these positions at any time, or purchase positions that have previously been sold. The positions may increase or decrease in value after the date hereof, and the portfolio that holds such positions may accordingly gain or lose money on the investment. The statements by the portfolio manager in its commentaries are intended to illustrate its approach in managing the portfolio and should not be relied upon for any other purpose. Certain information in this document has been derived or obtained from sources believed to be trustworthy and/or reliable. Neither Lysander nor Patient Capital assume responsibility for the accuracy, currency, reliability or correctness of any such information.

The S&P/TSX Composite Total Return Index is comprised of equity securities of some of the largest companies in Canada. The S&P 500 Index tracks the stock performance of 500 large companies listed on exchanges in the United States. An investor cannot invest directly in an index.

®Lysander Funds is a registered trademark of Lysander Funds Limited.